1
|
Pedersen OS, Butova T, Kapustnyk V, Miasoiedov V, Kuzhko M, Hryshchuk L, Kornaha S, Borovok N, Raznatovska O, Fedorec A, Bogomolov A, Tkhorovskiy M, Akymenko O, Klymenko I, Kulykova O, Karpenko Z, Shapoval T, Chursina N, Kondratyuk N, Parkhomenko O, Sazonenko I, Ostrovskyy M, Makoida I, Markovtsiy L, Skryp V, Lubenko V, Hrankina N, Bondarenko L, Hlynenko V, Dahl VN, Butov D. Treatment outcomes and risk factors for an unsuccessful outcome among patients with highly drug-resistant tuberculosis in Ukraine. Clin Microbiol Infect 2024; 30:360-367. [PMID: 38065363 DOI: 10.1016/j.cmi.2023.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Revised: 11/28/2023] [Accepted: 12/02/2023] [Indexed: 12/26/2023]
Abstract
OBJECTIVES To describe demographics, clinical features, and treatment outcomes of patients with highly drug-resistant tuberculosis (TB) in Ukraine, and to evaluate risk factors for an unsuccessful outcome. METHODS Data from patients with multi-, pre-extensively, or extensively drug-resistant TB were collected prospectively from TB dispensaries in 15 out of 24 Ukrainian oblasts (regions) from 2020 to 2021. Treatment outcomes were evaluated using WHO definitions. Risk factors for an unsuccessful outcome were identified using a multivariable logistic regression model. RESULTS Among 1748 patients, the overall proportion of successful outcomes was 58% (95% confidence interval [95% CI] 56-60) (n = 1015/1748), ranging from 65% (95% CI: 62-69) (n = 531/814) for multidrug-resistant TB to 54% (95% CI: 49-58) (n = 301/563) for pre-extensively drug-resistant TB and 49% (95% CI: 44-55) (n = 183/371) for extensively drug-resistant TB. Results were similar across oblasts, with few exceptions. The strongest risk factors for an unsuccessful outcome were extensively drug-resistant TB (adjusted OR [aOR] 3.23; 95% CI: 1.88-5.53), total serum protein below 62 g/L in adults and below 57 g/L for children and adolescents (aOR 2.79; 95% CI: 1.93-4.04), psychiatric illness (aOR 2.79; 95% CI: 1.46-5.33), age at TB diagnosis >65 years (aOR 2.50; 95% CI: 1.42-4.42), and alcohol misuse (aOR 2.48; 95% CI: 1.89-3.26). DISCUSSION The overall proportion of successful outcomes among Ukrainians treated for highly drug-resistant TB was 58%, notably better compared with previous years, but still low for extensively drug-resistant TB. Risk factors for unsuccessful outcomes highlight that addressing socioeconomic factors in TB management is crucial. Efforts in maintaining TB dispensaries during and following the ongoing war are highly warranted.
Collapse
Affiliation(s)
- Ole Skouvig Pedersen
- Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark
| | - Tetiana Butova
- Outpatient Department, Merefa Central District Hospital, Merefa, Ukraine
| | | | | | - Mykhailo Kuzhko
- Department of Chemoresistant Tuberculosis, National Institute of Phthisiology and Pulmonology named after F. G. Yanovskyi NAMS of Ukraine, Kiev, Ukraine
| | - Leonid Hryshchuk
- Department of Internal Medicine Propedeutics and Phthisiology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
| | - Svitlana Kornaha
- Department of Internal Medicine Propedeutics and Phthisiology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
| | - Natalia Borovok
- Medical Department No. 3, Regional Anti-tuberculosis Dispensary No 1 in Kharkiv, Kharkiv, Ukraine
| | - Olena Raznatovska
- Phthisiology and Pulmonology, Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine
| | - Andrii Fedorec
- The Pulmonary Tuberculosis Department No. 2, Zaporizhzhia Regional Phthisiology and Pulmonology Clinical Treatment and Diagnostic Center, Zaporizhzhia, Ukraine
| | - Artemii Bogomolov
- Phthisiology, Clinical Immunology and Allergology, National Pirogov Memorial Medical University, Vinnytsya, Ukraine
| | - Mykhaylo Tkhorovskiy
- Phthisiology, Clinical Immunology and Allergology, National Pirogov Memorial Medical University, Vinnytsya, Ukraine
| | - Oleksandra Akymenko
- Medical Department No. 3, Regional Anti-tuberculosis Dispensary No 1 in Kharkiv, Kharkiv, Ukraine
| | | | - Olena Kulykova
- Outpatient Department, Regional Clinical Tuberculosis Dispensary, Kramatorsk, Ukraine
| | - Zhanna Karpenko
- Phthisiatry Center, Chernihiv Regional Hospital, Chernihiv, Ukraine
| | - Tetiana Shapoval
- Phthisiatry Center, Chernihiv Regional Hospital, Chernihiv, Ukraine
| | | | - Natalia Kondratyuk
- Bacteriological Laboratory, Volyn Regional Phthisiopulmonological Center, Lutsk, Ukraine
| | - Olha Parkhomenko
- Mykolaiv Regional Phthisio-pulmonological Medical Center, Mykolaiv, Ukraine
| | - Inna Sazonenko
- Phthisiology, Mykolaiv Regional Phthisiology and Pulmonology Medical Center, Mykolaiv, Ukraine
| | - Mykola Ostrovskyy
- Phthisiology and Pulmonology Rate of Occupational Diseases, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
| | - Iryna Makoida
- Phthisiology and Pulmonology Rate of Occupational Diseases, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
| | | | - Vasyl Skryp
- Center of Pulmonary Diseases, Uzhhorod, Ukraine
| | - Victoriya Lubenko
- Information and Analytical Department, Phthisiopulmonology Center, Kyiv, Ukraine
| | - Nataliia Hrankina
- Infectious Diseases and Phthisiology, Krivoy Rig Tuberculosis Dispensary, Dnipro, Ukraine
| | - Leonid Bondarenko
- Administration, Sumy Regional Clinical Anti-tuberculosis Dispensary, Sumy, Ukraine
| | - Valentyna Hlynenko
- Outpatient Department, Sumy Regional Clinical Anti-tuberculosis Dispensary, Sumy, Ukraine
| | - Victor Næstholt Dahl
- Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; Center for Global Health, Aarhus University (GloHAU), Aarhus, Denmark; International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark.
| | - Dmytro Butov
- Infectious Diseases and Phthisiology, Kharkiv National Medical University, Kharkiv, Ukraine
| |
Collapse
|
2
|
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G, Fiterman J, Souza Machado A, Antila MA, Lima MA, Minamoto SET, Blanco DC, Bezerra PGDM, Houle PA, Lemiere C, Melenka LS, Leigh R, Mitchell P, Anees S, Pek B, Chouinard G, Cheema AS, Yang WHC, Philteos G, Chanez P, Bourdin A, Devouassoux G, Taille C, De Blay F, Leroyer C, Beurnier A, Garcia G, Girodet PO, Blanc FX, Magnan A, Wanin S, Just J, Linde R, Zielen S, Förster K, Geßner C, Jandl M, Buhl RO, Korn S, Kornmann MO, Linnhoff A, Ludwig-Sengpiel A, Ehlers M, Schmoller T, Steffen H, Hoffmann M, Kirschner J, Schmidt O, Welte T, Temme H, Wand O, Bar-Shai A, Izbicki G, Berkman N, Fink G, Shitrit D, Adir Y, Kuna P, Rewerska B, Pisarczyk-Bogacka E, Kurbacheva O, Mikhailov SL, Vasilev M, Emelyanov A, Wali S, Albanna A, van Zyl-Smit R, Abdullah I, Abdullah I, Bernhardi D, Hoosen F, Irusen E, Kalla I, Lakha D, Mitha E, Naidoo V, Nell H, Padayachee T, Reddy J, Petrick F, van der Walt E, Vawda ZFA, Park HS, Lee SH, Kim MK, Park JW, Cho YS, Lee BJ, Chang YS, Park CS, Lee KH, Lee SY, Yoon H, Sohn KH, Park MJ, Min KH, Cho YJ, Park HK, Lee Y, Lee J, Sheu CC, Tu CY, Lee KY, Bavbek S, Gemicioglu B, Ediger D, Kalkan IK, Makieieva N, Ostrovskyy M, Dytyatkovs'ka Y, Mostovoy YM, Lebed K, Yakovenko O, Adams A, Mooring T, Torres Jr L, Sexton M, Thompson E, Bernstein JA, Lisi P, Chappel CM, Cole J, Greenwald GI, Jones C, Klein RM, Pham DN, Spangenthal S, Weinstein SF, Windom HH, Kao NL, Leong MA, Mehta V, Moore WC, Bhat S, Aish B, Meltzer SM, Corren J, Moss MH, Kerwin EM, Delgado JP, Lucksinger GH, Thompson CA, Chupp G, Alpizar SA, Vadgama SV, Zafar Z, Jacobs JS, Lugogo NJ, Jain N, Sher LD, Andrawis NS, Fuentes D, Boren EJ, Gonzalez EG, Talreja N, Durrani SS, Israel E, Sekhsaria S, DeLeon S, Shukla M, Totszollosy Tarpay MM, Fakih F, Hudes G, Tillinghast JP, Korenblat PE, Shenoy K, Que L, Kureishy SA, Umeh FC, Nguyen VN, Chu HT, Nguyen TTD. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med 2023; 11:425-438. [PMID: 36702146 DOI: 10.1016/s2213-2600(22)00492-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Revised: 11/23/2022] [Accepted: 11/24/2022] [Indexed: 01/25/2023]
Abstract
BACKGROUND Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin. The drug has been tested previously in the phase 3 NAVIGATOR (NCT03347279) and SOURCE (NCT03406078) studies, and was subsequently approved as a treatment for severe asthma. This extension study recruited from NAVIGATOR and SOURCE and aimed to evaluate the long-term safety and efficacy of tezepelumab in individuals with severe, uncontrolled asthma. METHODS DESTINATION was a phase 3, multicentre, randomised, double-blind, placebo-controlled, long-term extension study. The study was done across 182 sites (including hospitals, clinics, medical centres, clinical trial centres, and private practices) in 18 countries. Participants (aged 12-80 years) were required to have good treatment compliance in the parent study. Randomisation was stratified by the parent study and all participants were re-randomised. Those who were previously randomised to receive tezepelumab in either parent study continued treatment of subcutaneous tezepelumab (210 mg every 4 weeks); those who were previously randomised to receive placebo in either parent study were re-randomised 1:1 to receive either subcutaneous tezepelumab (210 mg every 4 weeks) or placebo (every 4 weeks) using a randomisation list prepared by a computerised system. Total treatment duration (including the parent studies) was 104 weeks for all groups. Participants, investigators, and site staff were masked to treatment assignment. The primary endpoints were exposure-adjusted incidence of adverse events and serious adverse events and the secondary endpoint was the annualised asthma exacerbation rate; these were assessed from week 0 of the parent studies to week 104 of DESTINATION in all participants who were randomised and who received at least one dose of tezepelumab or placebo in either of the parent studies. The trial is registered with ClinicalTrials.gov, NCT03706079, and is closed to new participants. FINDINGS Participants were recruited between Jan 7, 2019, and Oct 15, 2020. For individuals who initially received tezepelumab (n=528) in NAVIGATOR, incidence of adverse events over 104 weeks was 49·62 (95% CI 45·16 to 54·39) per 100 patient-years, compared with 62·66 (56·93 to 68·81) for those receiving placebo (n=531; difference -13·04, 95% CI -17·83 to -8·18). For serious adverse events, incidence was 7·85 (6·14 to 9·89) per 100 patient-years for individuals who initially received tezepelumab and 12·45 (9·97 to 15·35) for those who received placebo (difference -4·59, -7·69 to -1·65). In SOURCE, incidence of adverse events was 47·15 (36·06 to 60·56) per 100 patient-years for those who initially received tezepelumab (n=74) and 69·97 (54·54 to 88·40) for those who received placebo (n=76; difference -22·82, -34·77 to -10·01). For serious adverse events, incidence was 13·14 (7·65 to 21·04) per 100 patient-years for those who initially received tezepelumab and 17·99 (10·66 to 28·44) for those who received placebo (difference -4·85, -14·88 to 4·53). Tezepelumab reduced the annualised asthma exacerbation rate over 104 weeks compared with placebo. In participants initially from NAVIGATOR, the annualised asthma exacerbation rate ratio over 104 weeks was 0·42 (95% CI 0·35 to 0·51); in those initially from SOURCE, the ratio over 104 weeks was 0·61 (0·38 to 0·96). INTERPRETATION Tezepelumab treatment was well tolerated for up to 2 years and resulted in sustained, clinically meaningful reductions in asthma exacerbations in individuals with severe, uncontrolled asthma. These findings are consistent with previous randomised, placebo-controlled studies and show the long-term safety and sustained efficacy of tezepelumab in individuals with severe, uncontrolled asthma. FUNDING AstraZeneca and Amgen.
Collapse
Affiliation(s)
- Andrew Menzies-Gow
- Department of Respiratory Medicine, Royal Brompton and Harefield Hospitals, School of Immunology and Microbial Sciences, King's College London, London, UK.
| | | | - Christopher E Brightling
- Institute for Lung Health, National Institute for Health and Care Research, Leicester Biomedical Research Centre, University of Leicester, Leicester, UK
| | - Stephanie Korn
- Pulmonary Department, Institute für klinische Forschung, Pneumologie Mainz, Mainz, Germany; Pulmonary Department, Thoraxklinik Heidelberg, Heidelberg, Germany
| | - Jonathan Corren
- Department of Medicine and Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | - Elliot Israel
- Division of Pulmonary and Critical Care Medicine and Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Geoffrey Chupp
- Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Yale School of Medicine, New Haven, CT, USA
| | - Artur Bednarczyk
- Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca Warsaw, Poland
| | - Sandhia Ponnarambil
- Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, UK
| | - Scott Caveney
- Global Development, Inflammation, Research and Development, Amgen, Thousand Oaks, CA, USA
| | - Gun Almqvist
- Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden
| | - Monika Gołąbek
- Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca Warsaw, Poland
| | - Linda Simonsson
- Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden
| | - Kaitlyn Lawson
- Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA; Cytel, Cambridge, MA, USA
| | - Karin Bowen
- Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA
| | - Gene Colice
- Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Myshchenko I, Ostrovskyy M, Kolhanov A, Makoida I, Hrechukh L. PREVALENCE OF SENSORY DYSFUNCTIONS IN ADULT UKRAINIAN POPULATION WITH LABORATORY CONFIRMED COVID-19. Wiad Lek 2022; 75:670-677. [PMID: 35522877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
OBJECTIVE The aim: To analyse the structure of sensory impairments, associated with COVID-19. To identify terms of recovery periods depending on severity of disease, age and gender of the patients. PATIENTS AND METHODS Materials and methods: Within two weeks, 2225 patients with confirmed COVID-19 completed a questionnaire, created by Google Forms. General complaints, peculiarities of sensory impairments and recovery time were specified. After exclusion criteria application, data of 2108 patients were analyzed by R Statistics Package, Student's t-test, Wilcoxon rank-sum test, Fisher's exact test, Spearman's rank test. RESULTS Results: Among patients enrolled (973 males and 1135 females, mean age 28.6±0.18) the most frequent were olfactory (91.32%) and gustatory (66.03%) dysfunctions. Olfactory manifestations were usually accompanied by gustatory disorders (73.72%). Average duration of olfactory dysfunction was 15.46±0.45 days, gustatory - 11.3±0.33, hearing - 4.3±0.16, and visual - 6.53±0.23 days. It was found a correlation between duration of olfactory and gustatory impairments (r=0.65; p < 0.001), hearing and visual disorders (r=0.49; p < 0.05). CONCLUSION Conclusions: Olfactory and gustatory disorders are prevalent symptoms in Ukrainian population. 7.87% of respondents who had impairment of all four sensory functions had the longest recovery time. Duration of sensory impairments did not depend on age, type of treatment and severity of disease, which rises the question about the neurogenic pathway of virus.
Collapse
Affiliation(s)
- Iryna Myshchenko
- DEPARTMENT HYGIENE AND ECOLOGY, IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE; ACCREDITED LABORATORY OF OCCUPATIONAL HEALTH AND SAFETY, WROCLAW UNIVERSITY OF SCIENCE TECHNOLOGY, WROCLAW, POLAND
| | - Mykola Ostrovskyy
- DEPARTMENT OF PHTHISIOLOGY AND PULMONOLOGY WITH COURSE OF OCCUPATIONAL DISEASES, IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE
| | - Anatolii Kolhanov
- DEPARTMENT HYGIENE AND ECOLOGY, IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE
| | - Iryna Makoida
- DEPARTMENT OF PHTHISIOLOGY AND PULMONOLOGY WITH COURSE OF OCCUPATIONAL DISEASES, IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE
| | - Lidiia Hrechukh
- DEPARTMENT HYGIENE AND ECOLOGY, IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE
| |
Collapse
|
4
|
Korzh N, Ostrovskyy M. Diagnostic Value of Leptin in Chronic Obstructive Pulmonary Disease of the Iii Degree in Patients with Excessive Body Weight. Galician med j 2019. [DOI: 10.21802/gmj.2019.4.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Chronic obstructive pulmonary disease (COPD) still remains a serious problem for the public health care system, since it commonly causes disability and mortality among the working population. Frequent combination of COPD with concomitant diseases is a key factor in predicting COPD consequences. Recently, the number of patients with a combination of COPD and overweight is on the increase, which is considered as a mutual aggravating factor and negatively affects the prognosis of the disease in such patients.
The objective of this study was to investigate the diagnostic value of leptin in progression of COPD (III degree of bronchial obstruction in patients with overweight) course by studying its level in blood serum.
Materials and methods: There were examined 112 patients with chronic obstructive pulmonary disease (COPD GOLD III) in different phases of pathological process. The pulmonary function (PF) test was performed by means of “SPIROKOM” device (Ukraine). The degree of overweight was determined by calculating the body mass index (BMI) using the formula І = m/h² (m – body mass in kilograms, h – height, in square meters (kg/m²). The level of leptin of systemic inflammatory markers was determined by a solid phase enzyme-linked immunosorbent assay in blood serum: “DRG Leptin Elisa” (Germany).
Results and conclusions: The study revealed that overweight leads to a more severe course of COPD (III degree of bronchial obstruction), and the determination of leptin may serve as a diagnostic criterion in the progression of this pathology.
Collapse
|
5
|
Hake HS, Davis JKP, Wood RR, Tanner MK, Loetz EC, Sanchez A, Ostrovskyy M, Oleson EB, Grigsby J, Doblin R, Greenwood BN. 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Physiol Behav 2019; 199:343-350. [PMID: 30529341 PMCID: PMC6557441 DOI: 10.1016/j.physbeh.2018.12.007] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Revised: 11/30/2018] [Accepted: 12/03/2018] [Indexed: 01/04/2023]
Abstract
Clinical trials have demonstrated that 3,4-methylenedioxymethamphetamine (MDMA) paired with psychotherapy is more effective at reducing symptoms of post-traumatic stress disorder (PTSD) than psychotherapy or pharmacotherapy, alone or in combination. The processes through which MDMA acts to enhance psychotherapy are not well understood. Given that fear memories contribute to PTSD symptomology, MDMA could augment psychotherapy by targeting fear memories. The current studies investigated the effects of a single administration of MDMA on extinction and reconsolidation of cued and contextual fear memory in adult, male Long-Evans rats. Rats were exposed to contextual or auditory fear conditioning followed by systemic administration of saline or varying doses of MDMA (between 1 and 10 mg/kg) either 30 min before fear extinction training or immediately after brief fear memory retrieval (i.e. during the reconsolidation phase). MDMA administered prior to fear extinction training failed to enhance fear extinction memory, and in fact impaired drug-free cued fear extinction recall without impacting later fear relapse. MDMA administered during the reconsolidation phase, but not outside of the reconsolidation phase, produced a delayed and persistent reduction in conditioned fear. These findings are consistent with a general memory-disrupting effect of MDMA and suggest that MDMA could augment psychotherapy by modifying fear memories during reconsolidation without necessarily enhancing their extinction.
Collapse
Affiliation(s)
- Holly S Hake
- Department of Psychology, University of Colorado Denver, PO Box 173364, Denver, CO 80217-3364, USA.
| | - Jazmyne K P Davis
- Department of Psychology, University of Colorado Denver, PO Box 173364, Denver, CO 80217-3364, USA.
| | - River R Wood
- Department of Psychology, University of Colorado Denver, PO Box 173364, Denver, CO 80217-3364, USA.
| | - Margaret K Tanner
- Department of Psychology, University of Colorado Denver, PO Box 173364, Denver, CO 80217-3364, USA.
| | - Esteban C Loetz
- Department of Psychology, University of Colorado Denver, PO Box 173364, Denver, CO 80217-3364, USA.
| | - Anais Sanchez
- Department of Psychology, University of Colorado Denver, PO Box 173364, Denver, CO 80217-3364, USA.
| | - Mykola Ostrovskyy
- Department of Psychology, University of Colorado Denver, PO Box 173364, Denver, CO 80217-3364, USA.
| | - Erik B Oleson
- Department of Psychology, University of Colorado Denver, PO Box 173364, Denver, CO 80217-3364, USA.
| | - Jim Grigsby
- Department of Psychology, University of Colorado Denver, PO Box 173364, Denver, CO 80217-3364, USA; Department of Medicine, University of Colorado Denver School of Medicine, Anschutz Medical Campus, Aurora, CO 80045, USA.
| | - Rick Doblin
- Multidisciplinary Association for Psychedelic Studies, 1115 Mission Street, Santa Cruz, CA 95060-9989, USA
| | - Benjamin N Greenwood
- Department of Psychology, University of Colorado Denver, PO Box 173364, Denver, CO 80217-3364, USA.
| |
Collapse
|
6
|
Melnyk-Sheremeta O, Ostrovskyy M. Influence of Glucosaminilemuramylpentapeptide on the Functional Peculiarities of the Respiratory System and the Dynamics of IL-6 in Patients with Infiltrative Tuberculosis Combined with Chronic Bronchitis. Galician med j 2017. [DOI: 10.21802/gmj.2017.3.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
The aim of our study was to evaluate the functional peculiarities of the respiratory system and the dynamics of IL-6 in patients with infiltrative tuberculosis combined with chronic bronchitis.Materials and methods. There were examined 40 patients with infiltrative tuberculosis combined with chronic bronchitis: 18 patients receiving basic therapy according to the category and 22 patients who were added glucosaminilemuramylpentapeptide to basic therapy. Determination of IL-6 in bronchoalveolar content was performed by ELISA analysis.Results. The additional inclusion of glucosaminilemuramylpentapeptide into the complex therapy of patients with infiltrative tuberculosis combined with chronic bronchitis in acute phase manifests itself with positively aimed dynamic changes of the bronchial mucous membrane according to the data of endoscopy. The standard scheme of treatment combined with immune modulator affects the recovery of lung function in comorbidity of pathologies explaining it as the action of the means aimed at enhancing of sanogenetic mechanisms of liquidation of combination of specific and nonspecific inflammation in the broncho-pulmonary system, and thus – the reduction of the basis for secondary bronchial obstruction. The results of this study indicate the advisability of administration of immune modulator of muramylpeptide series.
Collapse
|
7
|
Bouchet CA, Lloyd BA, Loetz EC, Farmer CE, Ostrovskyy M, Haddad N, Foright RM, Greenwood BN. Acute exercise enhances the consolidation of fear extinction memory and reduces conditioned fear relapse in a sex-dependent manner. ACTA ACUST UNITED AC 2017; 24:358-368. [PMID: 28716955 PMCID: PMC5516683 DOI: 10.1101/lm.045195.117] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2017] [Accepted: 05/08/2017] [Indexed: 11/25/2022]
Abstract
Fear extinction-based exposure therapy is the most common behavioral therapy for anxiety and trauma-related disorders, but fear extinction memories are labile and fear tends to return even after successful extinction. The relapse of fear contributes to the poor long-term efficacy of exposure therapy. A single session of voluntary exercise can enhance the acquisition and consolidation of fear extinction in male rats, but the effects of exercise on relapse of fear after extinction are not well understood. Here, we characterized the effects of 2 h of voluntary exercise during the consolidation phase of contextual or auditory fear extinction learning on long-term fear extinction memory and renewal in adult, male and female, Long-Evans rats. Results indicate that exercise enhances consolidation of fear extinction memory and reduces fear relapse after extinction in a sex-dependent manner. These data suggest that brief bouts of exercise could be used as an augmentation strategy for exposure therapy, even in previously sedentary subjects. Fear memories of discrete cues, rather than of contextual ones, may be most susceptible to exercise-augmented extinction, especially in males. Additionally, exercise seems to have the biggest impact on fear relapse phenomena, even if fear extinction memories themselves are only minimally enhanced.
Collapse
Affiliation(s)
- Courtney A Bouchet
- Department of Psychology, University of Colorado Denver, Denver, Colorado 80217, USA
| | - Brian A Lloyd
- Department of Psychology, University of Colorado Denver, Denver, Colorado 80217, USA
| | - Esteban C Loetz
- Department of Psychology, University of Colorado Denver, Denver, Colorado 80217, USA
| | - Caroline E Farmer
- Department of Psychology, University of Colorado Denver, Denver, Colorado 80217, USA
| | - Mykola Ostrovskyy
- Department of Psychology, University of Colorado Denver, Denver, Colorado 80217, USA
| | - Natalie Haddad
- Department of Psychology, University of Colorado Denver, Denver, Colorado 80217, USA
| | - Rebecca M Foright
- Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, USA
| | - Benjamin N Greenwood
- Department of Psychology, University of Colorado Denver, Denver, Colorado 80217, USA
| |
Collapse
|